Compile Data Set for Download or QSAR
maximum 50k data
Found 448 of ic50 for UniProtKB: P01584
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531296(US11208399, Example 53)
Affinity DataIC50:  0.400nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531223((R)-2-(4-Methyl-6-((1-methylpiperidin-3-yl)amino)p...)
Affinity DataIC50:  0.400nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM65497(CC-220 (Compound 6) | US9694015, 6.4S)
Affinity DataIC50:  0.460nMT: 2°CAssay Description:The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a ⿿20° C. freezer p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531253(US11208399, Example 12)
Affinity DataIC50:  0.600nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531331(US11208399, Example 82)
Affinity DataIC50:  0.700nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531332(US11208399, Example 83a)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531288(US11208399, Example 47)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531289(US11208399, Example 48)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531319(US11208399, Example 71)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531220((R)-2-(6-((1-Ethylpiperidin-3-yl)amino)pyridazin-3...)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM77001(3-(4-((4-(morpholinomethyl)benzyl)-oxy)-1-oxoisoin...)
Affinity DataIC50:  0.850nMT: 2°CAssay Description:The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a ⿿20° C. freezer p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531230(US11208399, Example 6)
Affinity DataIC50:  0.900nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531254(US11208399, Example 13)
Affinity DataIC50:  1.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531337(3-Methyl-2-(6-(((1R,2R,5R)-8-methyl-8-azabicyclo[3...)
Affinity DataIC50:  1.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531252(US11208399, Example 11)
Affinity DataIC50:  1.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531354(2-(6-(((3S, 5S)-5-Fluoro-1-methylpiperidin-3-yl)am...)
Affinity DataIC50:  1.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531291(US11208399, Example 49)
Affinity DataIC50:  1.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531339(2-(6-(((1S,2S,5S)-8-(2-Hydroxyethyl)-8-azabicyclo[...)
Affinity DataIC50:  1.80nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531364((R)-2-(6-((1-Ethylpiperidin-3-yl)amino)-5-methylpy...)
Affinity DataIC50:  1.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531232(US11208399, Example 7)
Affinity DataIC50:  1.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531292(US11208399, Example 50)
Affinity DataIC50:  2.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531293(US11208399, Example 51)
Affinity DataIC50:  2.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531323(US11208399, Example 74)
Affinity DataIC50:  2.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531224((R)-3-Methyl-2-(5-methyl-6-((1-methylpiperidin-3-y...)
Affinity DataIC50:  3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531282(US11208399, Example 41)
Affinity DataIC50:  3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531286(US11208399, Example 45)
Affinity DataIC50:  3.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531279(US11208399, Example 39)
Affinity DataIC50:  3.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531350(2-(6-(((R)-1-((S)-2-Hydroxypropyl)piperidin-3-yl)a...)
Affinity DataIC50:  3.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531318(US11208399, Example 70)
Affinity DataIC50:  3.5nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531351(2-(6-(((R)-1-((R)-2-Hydroxypropyl)piperidin-3-yl)a...)
Affinity DataIC50:  3.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531329(US11208399, Example 80)
Affinity DataIC50:  4.70nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531310(US11208399, Example 64)
Affinity DataIC50:  5.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531363((R)-3-Methyl-2-(5-methyl-6-(piperidin-3-ylamino)py...)
Affinity DataIC50:  6nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM77015((R)-3-(4-((4-(morpholinomethyl)benzyl)-oxy)-1-oxoi...)
Affinity DataIC50:  6.20nMT: 2°CAssay Description:The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a ⿿20° C. freezer p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531340(2-(6-(((3R,6R)-6-(Hydroxymethyl)-1-methylpiperidin...)
Affinity DataIC50:  6.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531352(2-(6-(((3S,5S)-5-Fluoropiperidin-3-yl)amino)pyrida...)
Affinity DataIC50:  6.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531280(US11208399, Example 40)
Affinity DataIC50:  6.80nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531311(US11208399, Example 65)
Affinity DataIC50:  7.40nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531360((3S,5R)-5-((6-(2-Hydroxy-6-methyl-4-(trifluorometh...)
Affinity DataIC50:  7.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531302(US11208399, Example 56)
Affinity DataIC50:  8.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398217(4-chloro-N-((3, 3-difluoro-1-hydroxycyclohexyl)met...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398218(4-chloro-N-((3,3-difluorocyclohexyl)methyl)-1-(pyr...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398219(4-chloro-N-((3,3-difluoro-5-methylcyclohexyl)methy...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398220(4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-((1-...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398233(4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(pip...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398106(Preparations of 4-chloro-N-((4,4-difluorocyclohexy...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398117(4-chloro-1-(oxetan-3-yl)-N-((1-(4-phenylpiperazin-...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398217(4-chloro-N-((3, 3-difluoro-1-hydroxycyclohexyl)met...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM398218(4-chloro-N-((3,3-difluorocyclohexyl)methyl)-1-(pyr...)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM450448(US10676433, Compound 158 | US10676433, Compound 76)
Affinity DataIC50: <10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 448 total ) | Next | Last >>
Jump to: